Intended for healthcare professionals

Rapid response to:

News Extra [these Stories Appear Only On The Web]

Creator of Dolly the sheep applies for therapeutic cloning licence

BMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7447.1036-a (Published 29 April 2004) Cite this as: BMJ 2004;328:1036

Rapid Response:

Therapeutic Cloning!

Dear Sir:

This "NEWS EXTRA" is very stimulating probably not only to me but
also other researchers and like-minded people in the sense that Prof.
Wilmut has reportedly applied for therapeutic cloning licence in the UK.
Professor Ian Wilmut is well-known for his work on cloning of sheep
"Dolly" for the first time and his work produced a mixed hype around the
world because of associated ethical issues related in particular to that
this scientific work will lead to human cloning. Public at large and
licencing authorities should understand that this licencing is for
therapeutic cloning in order to clon certain cells for example motor
neurons for the treatment of motor neuron disease [MND], which is
extremely crippling and associated with high mortality rate. Arguably,
licencing authorities must plug any loophole for abusing this lincence if
given to Professor Wilmut. However, refusing this licence belatantly by
relevant licence governing authorities would harm the interests of people
who suffer from MND and die of it at very early age after the diagnosis of
this devastating neurological disease. Notably, the therapeutic cloning
will aslo be useful therapeutically in other crippling diseases that
affect humans globally.

Reference:

Nadeeja Koralage. Creator of Dolly the sheep applies for therapeutic
cloning licence. BMJ 2004; 328: 1036-a-0-a

Competing interests:
Pro-researcher and pro-life supporter

Competing interests: No competing interests

05 May 2004
Dr. Naseem A. Qureshi MD, IMAPA, LMIPS
Medical Director(A), Director CME&R
Buraidah Mental Health Hospital, Postcode:2292, Saudi Arabia